---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-124226"
form_type: "8-K/A"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2025-12-23T23:59:59+00:00"
generated_at: "2026-05-16T12:17:21.543235+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TransCode files ABCJ financials; acquired co's accumulated deficit $193M, DEFJ holds 90.8% voting power

## Summary
- ABCJ (parent of Polynoma) reported 2024 net loss of $16.4M and accumulated deficit of $193M.
- Key asset is phase 3-ready seviprotimut-L for melanoma; intangible asset valued at $14M.
- Post-acquisition, DEFJ holds ~90.8% voting power on fully diluted basis, raising controlled-company concerns.
- Acquisition carries a repurchase option for DEFJ, potentially requiring cash settlement and disrupting operations.
- Pro forma combined financial statements for Sep 30, 2025 and Dec 31, 2024 filed as Exhibit 99.3.

## SEC filing metadata
- accession: 0001104659-25-124226
- form_type: 8-K/A
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2025-12-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465925124226/0001104659-25-124226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465925124226/tm2533321d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-124226
- JSON: https://secwatch.observer/filing/0001104659-25-124226.json
- Plain text: https://secwatch.observer/filing/0001104659-25-124226.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.